Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
In patients with obesity and knee osteoarthritis, once-weekly semaglutide (2.4 mg) significantly reduced body weight and pain compared to placebo, though it was associated with gastrointestinal side effects.
In adults with obesity (BMI ≥30 kg/m²), daily subcutaneous semaglutide significantly promoted weight loss compared to liraglutide and placebo, with gastrointestinal symptoms as the main side effect.
In patients with type 2 diabetes, once-weekly semaglutide significantly improved glycaemic control (HbA1c reduction) and reduced body weight in a dose-dependent manner compared to placebo, with efficacy at the highest doses surpassing that of daily liraglutide, though it was associated with gastrointestinal side effects.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
